Drug intelligence / Profile preview

Tianaa Red

Development stage
Unknown
Lead developer
Premier Manufacturing Products
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

**Tianaa Red** is an orally administered, multi-ingredient product sold in the United States as a dietary supplement but identified by the FDA as an unapproved new drug. It contains the synthetic atypical tricyclic antidepressant **tianeptine** and kava leaf extract; analytical testing found variable tianeptine content and identified kava-derived kavapyrones. Tianeptine is a small-molecule mu-type opioid receptor agonist associated with opioid-like intoxication, dependence, withdrawal, overdose, and death at high or repeated exposures. Tianaa Red has been promoted for relaxation, stress relief, and related effects, but it is not FDA-approved for any medical use and FDA considers tianeptine an unsafe food additive. ([fda.gov](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/premier-manufacturing-products-llc-678912-07022024))

Brand names
Tianaa Red
02

Targets

DRD3 (Dopamine receptor D3)GRIA1 (AMPA receptor subunit GluA1)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on Tianaa Red.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tianaa Red.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call